Usual dietary treatment of gestational diabetes mellitus assessed after control diet in randomized controlled trials : subanalysis of a systematic review and meta-analysis by García-Patterson, A. et al.
Vol.:(0123456789) 
Acta Diabetologica (2019) 56:237–240 
https://doi.org/10.1007/s00592-018-1238-4
SHORT COMMUNICATION
Usual dietary treatment of gestational diabetes mellitus assessed 
after control diet in randomized controlled trials: subanalysis 
of a systematic review and meta-analysis
Apolonia García‑Patterson1 · Montserrat Balsells2 · Jennifer M. Yamamoto3 · Joanne E. Kellett4 · Ivan Solà1,5,6 · 
Ignasi Gich6,7,8,9 · Eline M. van der Beek10,11 · Eran Hadar12 · Eurídice Castañeda‑Gutiérrez13 · Seppo Heinonen14,15 · 
Moshe Hod12 · Kirsi Laitinen16,17 · Sjurdur F. Olsen18 · Lucilla Poston19 · Ricardo Rueda20 · Petra Rust21 · 
Lilou van Lieshout22 · Bettina Schelkle22 · Helen R. Murphy4,23,24 · Rosa Corcoy25,26,27
Received: 8 August 2018 / Accepted: 26 September 2018 / Published online: 17 October 2018 
© The Author(s) 2018
Abbreviations
DRI  Dietary reference intakes
GDM  Gestational diabetes mellitus
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Introduction
The prevalence of GDM is on the rise in relation to an 
increase in predisposing maternal characteristics. The 
increase is more marked with application of IADPSG-WHO 
2013 criteria [1], with very high rates in special populations 
[2].
Lifestyle modifications are the first step in the manage-
ment of GDM and medical nutrition therapy is an essential 
component of it. Maternal diet should provide adequate 
energy intake to promote maternal and fetal health, help 
achieve glycemic goals and be culturally appropriate and 
individualized [3]. DRI for normal weight pregnant women 
should be taken into account: provide no increase in energy 
requirement during the first trimester, + 340 kcal/day in 
the second trimester and + 452 kcal/day in the third; pro-
vide > = 175 g carbohydrate/day, 71 g protein/day and 28 g 
fiber/day; and have an acceptable energy macronutrient 
distribution range (45–65% of energy from carbohydrates, 
20–35% of energy from fat, 10–35% of energy from protein). 
However, little is known about the characteristics of diets 
consumed by women with GDM.
We aimed to characterize the dietary intake of women 
with GDM in usual clinical care.
Study protocol
We recently performed a systematic review and meta-anal-
ysis on RCTs addressing modified dietary interventions for 
the treatment of GDM and providing information on mater-
nal glycemic control and birthweight-related variables [4] 
(published protocol: PROSPERO CRD42016042391).
As a post hoc analysis, we have now examined the com-
position of diets used by the control group to character-
ize diets advised for treatment of GDM in usual clinical 
care. Data on ten dietary characteristics (kcal/day, % of 
energy provided by carbohydrates, protein, fat, monoun-
saturated fat, saturated fat and polyunsaturated fat, grams 
of fiber/day, glycemic index and load) were collected. 
Glycemic index is defined as the incremental area under 
the blood glucose curve following the ingestion of a test 
food, expressed as percentage of the corresponding area 
following an equivalent load of a reference carbohydrate. 
The glycemic load takes into account the amount of food 
intake.
We have used STATA 14.0 and a random effects model 
to pool the diet characteristics. Heterogeneity was assessed 
using I2 statistics and Cochran’s Q test. A figure display-
ing worldwide carbohydrate energy contribution was con-
structed using the carbohydrate intake of studies providing 
this information (filled circle) and carbohydrate advice (open 
circle) when intake was not available.
Managed by Antonio Secchi.
Helen M. Murphy and Rosa Corcoy, senior authors, contributed 
equally.
 * Rosa Corcoy 
 rcorcoy@santpau.cat
Extended author information available on the last page of the article
238 Acta Diabetologica (2019) 56:237–240
1 3
Results
Out of 3660 records identified through database search and 
128 from other sources, 126 full-text articles were assessed 
for eligibility and 18 studies were included in the meta-anal-
ysis of glycemic control and birthweight-related variables 
[4]. Thirteen of these studies provided quantitative informa-
tion on one or more diet characteristics and were included 
in the current meta-analysis and graphical display. The car-
bohydrate intake was the diet characteristic most frequently 
reported (N = 12). Other studies only reported diet recom-
mendations and the four of them giving data on carbohydrate 
advice were included for graphical display.
In the 13 studies included in the current analysis, the 
modified dietary intervention used for treatment of GDM 
was as follows: a low glycemic index diet (N = 4), a low 
carbohydrate diet (N = 1), Dietary Approaches to Stop 
Hypertension (N = 3), modification of dietary fat (N = 2), soy 
protein enrichment (N = 1), behavioral intervention (N = 1), 
and calorie restriction (N = 1). The information in the inter-
vention arm is not used in the current analysis.
Pooled estimates on control diet characteristics are sum-
marized in Table 1. High heterogeneity was observed in the 
ten diet characteristics (I2 ranging from 94.8 for glycemic 
load to 99.2 for % of energy from polyunsaturated fat; p for 
heterogeneity < 0.001 for all of them).
The dietary carbohydrate content of control diets in indi-
vidual trials is displayed in Fig. 1. Carbohydrate contribution 
to energy intake ranged from moderate restriction (36.2% in 
Australia) to the upper range of the acceptable macronutrient 
distribution range (60.0%, Poland).
Table 1  Characteristics of 
control diet in RCTs addressing 
modified dietary interventions 
for GDM treatment (pooled 
estimates)
Characteristic N studies Median CI 95% I2 P heterogeneity
Energy (Kcal/day) 10 2094.0 1931.9–2256 98.1 < 0.001
% of energy from carbohydrates 12 49.1 45.1–53.1 98.5 < 0.001
% of energy from proteins 11 19.0 17.1–20.9 98.5 < 0.001
% of energy from total fat 11 31.5 28.6–34.4 97.7 < 0.001
% of energy from saturated fat 7 9.6 8.3–10.8 96.6 < 0.001
% of energy from polyunsaturated fat 6 9.5 8.3–10.7 99.2 < 0.001
% of energy from monounsaturated fat 3 10.1 6.1–14.1 96.8 < 0.001
Glycemic index 4 54.3 51.2–57.5 98.1 < 0.001
Glycemic load 3 122.3 108.1–136.4 94.8 < 0.001
Fiber (g/day) 10 21.6 18.9–24.2 98.0 < 0.001
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Fig. 1  Energy derived from carbohydrates in control diets of RCTs addressing modified dietary interventions for treatment of GDM by trial site
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Discussion
In this subanalysis addressing control diets in RCTs on 
modified dietary interventions for GDM, we observed a 
high heterogeneity in the ten analyzed characteristics. This 
information has not been previously reported.
The figures of carbohydrate content of control diets paral-
lel with some exceptions the diet composition in the back-
ground population according to FAO statistics [5] with the 
incorporation of some degree of carbohydrate restriction.
It is of note that specific dietary recommendations with 
regard to energy-yielding nutrients are lacking for treatment 
of GDM. A limitation of the current analysis is that we did 
not perform a specific systematic review and meta-analysis 
to address this topic but a subanalysis of a previous one [4]. 
However, current results can serve as an estimation of diets 
usually advised to women with GDM. Another limitation 
is that the number of meals and snacks was not addressed.
We conclude that control diets used in RCTs addressing 
modified dietary intervention in women with GDM display 
marked heterogeneity in all analyzed characteristics, prob-
ably reflecting the diet properties of the background popula-
tion. This is desirable from the cultural and socioeconomic 
point of view, but may have an impact on the response to 
nutritional management of GDM and should be addressed 
in future research.
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